Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Market Cap
$13.02B
P/E Ratio
19.61
1Y Stock Return
-33.87%
1Y Revenue Growth
18.04%
Dividend Yield
0.00%
Price to Book
2.7
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PULM | -16.31% | $19.83M | +202.98% | 0.00% |
PRPO | -15.39% | $9.10M | -13.65% | 0.00% |
SPR | -11.68% | $3.72B | +23.27% | 0.00% |
BTCT | -10.50% | $42.61M | +353.33% | 0.00% |
BCAN | -8.94% | $72.87M | -99.75% | 0.00% |
HUSA | -8.89% | $16.69M | -11.56% | 0.00% |
ERIE | -7.76% | $19.39B | +46.23% | 1.23% |
CEG | -7.73% | $73.37B | +91.48% | 0.59% |
APRE | -6.83% | $16.41M | -19.47% | 0.00% |
RNR | -6.77% | $13.74B | +23.09% | 0.58% |
NOC | -6.72% | $71.54B | +4.23% | 1.60% |
TCTM | -6.59% | $8.10M | -42.99% | 0.00% |
EDSA | -6.48% | $7.11M | -21.79% | 0.00% |
UNM | -5.92% | $13.16B | +69.20% | 2.16% |
FATBB | -5.85% | $81.94M | -12.91% | 11.69% |
SAIA | -5.81% | $13.72B | +22.08% | 0.00% |
LPTH | -5.62% | $62.27M | +33.05% | 0.00% |
LPLA | -4.79% | $23.55B | +38.13% | 0.38% |
CME | -4.68% | $82.76B | +9.21% | 1.98% |
CAVA | -4.45% | $16.15B | +322.78% | 0.00% |
Yahoo
We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly optimistic about US equities. Its portfolio managers opine that there […]
SeekingAlpha
Harding Loevner International Equity ADR composite rose 9.2%, gross, in Q3 2024, outpacing the 8.2% gain of the MSCI All Country ex US Index. Click here to read more.
SeekingAlpha
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ETCompany ParticipantsJan van de Winkel - CEOBrad Bailey - EVP and Chief...
SeekingAlpha
The following slide deck was published by Genmab A/S in conjunction with their 2024 Q3 earnings call.
Yahoo
In a week marked by intense economic and earnings activity, global markets experienced varied performances with the technology-heavy Nasdaq Composite and S&P MidCap 400 Index hitting record highs before pulling back, while small-cap stocks showed resilience compared to their larger counterparts. As growth stocks lagged behind value shares amid cautious earnings reports from major tech players, identifying promising high-growth tech stocks requires careful consideration of fundamentals such as...
Yahoo
Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in early-stage programs.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DHT | -0.02% | $1.72B | +5.04% | 9.18% |
BACK | -0.03% | $1.76M | -32.90% | 0.00% |
COR | -0.04% | $47.48B | +21.20% | 0.86% |
TXMD | -0.05% | $14.99M | -53.32% | 0.00% |
MSB | -0.07% | $337.71M | +30.73% | 5.15% |
PANW | -0.07% | $126.99B | +46.98% | 0.00% |
ALAR | 0.07% | $89.09M | +158.08% | 0.00% |
CLMT | 0.09% | $1.79B | +35.14% | 0.00% |
BVN | -0.09% | $3.16B | +37.49% | 0.00% |
AGL | 0.11% | $655.11M | -85.55% | 0.00% |
CMG | 0.12% | $80.02B | +33.62% | 0.00% |
CORZ | -0.13% | $4.60B | +3,201.26% | 0.00% |
NNVC | -0.15% | $19.66M | +25.69% | 0.00% |
BJ | 0.17% | $11.45B | +32.57% | 0.00% |
TPST | -0.24% | $37.75M | -77.59% | 0.00% |
BEST | -0.24% | $31.65M | +3.88% | 0.00% |
AIZ | -0.25% | $11.24B | +33.00% | 1.31% |
NAT | -0.26% | $636.83M | -30.05% | 13.79% |
AXS | 0.27% | $7.14B | +55.12% | 2.06% |
GAN | -0.28% | $83.39M | +21.19% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
JYNT | 42.14% | $164.07M | +24.57% | 0.00% |
CLFD | 41.58% | $398.66M | +4.48% | 0.00% |
VIR | 40.68% | $954.40M | -26.51% | 0.00% |
AMGN | 40.57% | $150.48B | +6.52% | 3.20% |
BIO | 39.49% | $8.98B | +4.73% | 0.00% |
QGEN | 39.24% | $9.05B | -1.92% | 0.00% |
BIIB | 38.38% | $22.65B | -32.30% | 0.00% |
FLGT | 38.38% | $519.98M | -37.82% | 0.00% |
PGEN | 38.28% | $228.91M | -28.00% | 0.00% |
SON | 38.14% | $4.83B | -10.64% | 4.20% |
ORA | 37.88% | $4.80B | +20.68% | 0.61% |
TECH | 37.63% | $10.55B | +4.49% | 0.48% |
KBH | 36.80% | $5.71B | +46.75% | 1.21% |
CVCO | 36.59% | $3.82B | +69.11% | 0.00% |
CRSP | 36.58% | $4.01B | -30.49% | 0.00% |
TMHC | 36.06% | $7.19B | +55.90% | 0.00% |
ATNM | 35.68% | $44.30M | -67.05% | 0.00% |
NLY | 35.57% | $11.07B | +11.39% | 13.23% |
AGNC | 35.56% | $8.56B | +9.64% | 14.95% |
DX | 35.53% | $991.29M | +9.75% | 12.54% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -29.95% | $388.04M | 1.43% |
VIXY | -27.00% | $195.31M | 0.85% |
USDU | -23.73% | $201.97M | 0.5% |
UUP | -21.12% | $309.25M | 0.77% |
CTA | -18.10% | $350.27M | 0.78% |
EQLS | -14.27% | $76.08M | 1% |
DBO | -12.74% | $217.57M | 0.77% |
SOYB | -11.48% | $27.32M | 0.22% |
COMT | -11.34% | $829.06M | 0.48% |
DBE | -11.30% | $50.13M | 0.77% |
TAIL | -11.06% | $67.98M | 0.59% |
HIGH | -10.12% | $302.78M | 0.51% |
GSG | -10.08% | $914.42M | 0.75% |
KCCA | -9.84% | $220.51M | 0.87% |
KMLM | -9.77% | $353.87M | 0.9% |
DBC | -9.18% | $1.39B | 0.87% |
WEAT | -8.87% | $120.27M | 0.28% |
PDBC | -8.67% | $4.40B | 0.59% |
USCI | -8.54% | $185.47M | 1.07% |
CORN | -8.26% | $61.12M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZD | -0.18% | $142.76M | 0.23% |
MINT | -0.50% | $11.62B | 0.35% |
GCC | 0.53% | $133.23M | 0.55% |
TPMN | -0.60% | $40.60M | 0.65% |
BOXX | -0.89% | $4.43B | 0.1949% |
PHDG | 1.45% | $113.97M | 0.39% |
CMDY | -1.62% | $279.14M | 0.28% |
FMF | -1.78% | $244.61M | 0.95% |
BSCO | 2.68% | $2.35B | 0.1% |
CLOI | -3.13% | $715.40M | 0.4% |
BCD | -3.49% | $245.02M | 0.3% |
DBMF | 3.83% | $1.02B | 0.85% |
SGOV | 4.65% | $27.53B | 0.09% |
BCI | -4.78% | $1.20B | 0.26% |
IBTE | 5.00% | $1.70B | 0.07% |
BILZ | -5.01% | $563.02M | 0.14% |
FTGC | -5.13% | $2.17B | 1.02% |
CANE | -5.35% | $17.72M | 0.29% |
GBIL | -5.67% | $5.60B | 0.12% |
XLE | 5.68% | $37.90B | 0.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FBT | 55.54% | $1.11B | 0.56% |
IBB | 55.34% | $6.66B | 0.45% |
BBH | 53.45% | $397.87M | 0.35% |
PBE | 51.04% | $258.53M | 0.58% |
RSPH | 50.54% | $885.96M | 0.4% |
FXH | 48.32% | $1.15B | 0.62% |
XBI | 47.32% | $6.58B | 0.35% |
GNOM | 46.78% | $70.59M | 0.5% |
IXJ | 46.53% | $3.89B | 0.41% |
FHLC | 46.09% | $2.73B | 0.084% |
VHT | 46.02% | $17.06B | 0.1% |
ARKG | 45.29% | $1.13B | 0.75% |
EFAA | 45.00% | $117.38M | 0% |
SCHY | 44.36% | $775.05M | 0.14% |
PRNT | 43.76% | $95.35M | 0.66% |
IYH | 43.45% | $3.19B | 0.39% |
MOAT | 43.08% | $15.73B | 0.46% |
XLV | 43.05% | $38.41B | 0.09% |
IDLV | 42.99% | $252.07M | 0.25% |
QEFA | 42.98% | $914.41M | 0.3% |
Current Value
$20.491 Year Return
Current Value
$20.491 Year Return